NASDAQ: FATEFate Therapeutics Inc Stock
$2.12-0.06 (-2.75%)
Updated Sep 29, 2023
FATE Price
$2.12
Fair Value Price
$2.55
Market Cap
$208.95M
52 Week Low
$1.99
52 Week High
$23.96
P/E
-0.98x
P/B
0.48x
P/S
3.93x
PEG
N/A
Dividend Yield
N/A
Revenue
$119.25M
Earnings
-$211.56M
Gross Margin
100%
Operating Margin
-177.41%
Profit Margin
-177.4%
Debt to Equity
0.34
Operating Cash Flow
-$188M
Beta
1.59
Next Earnings
Nov 1, 2023
Ex-Dividend
N/A
Next Dividend
N/A
FATE Overview
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Zen Score
–
Industry Average (25)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how FATE scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
FATE ($2.12) is undervalued by 16.81% relative to our estimate of its Fair Value price of $2.55 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
FATE ($2.12) is not significantly undervalued (16.81%) relative to our estimate of its Fair Value price of $2.55 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
FATE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more FATE due diligence checks available for Premium users.
Be the first to know about important FATE news, forecast changes, insider trades & much more!
FATE News
Valuation
FATE fair value
Fair Value of FATE stock based on Discounted Cash Flow (DCF)
Price
$2.12
Fair Value
$2.55
Undervalued by
16.81%
FATE ($2.12) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
FATE ($2.12) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
FATE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
FATE price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.98x
Industry
13.67x
Market
12.37x
FATE price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.48x
Industry
5.09x
FATE is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
FATE's financial health
Profit margin
Revenue
$933.0k
Net Income
-$52.8M
Profit Margin
-5,654.3%
FATE's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
FATE's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$584.8M
Liabilities
$147.0M
Debt to equity
0.34
FATE's short-term assets ($392.18M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
FATE's short-term assets ($392.18M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
FATE's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
FATE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$28.5M
Investing
$33.2M
Financing
$58.0k
FATE's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
FATE vs Biotech Stocks
Fate Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.